Brief: GH Research Initiates Mid-stage Study In Treatment-Resistant Depression
02/03/2023 12:29
March 2 (Reuters) - GH Research PLC GHRS.O :
* GH RESEARCH - RECENTLY INITIATED MULTI-CENTER, RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL OF GH001 IN
TREATMENT-RESISTANT DEPRESSION
* GH RESEARCH PLC - BELIEVE EXISTING CASH & CASH EQUIVALENTS
TO BE
SUFFICIENT TO FUND OUR OPERATING EXPENSES, CAPEX REQUIREMENTS
INTO 2026
Source text for Eikon: ID:nGNX9fYlMY
Further company coverage: GHRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GH Research
See all newsCorrected: UPDATE 2-Experts urge FDA to set clear safety and access standards for psychedelic drugs (September 14)
FDA to hold public hearing on psychedelic drugs as Trump-driven push gathers pace
Ireland's GH Research Q2 net loss widens on higher R&D costs
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Street View: Psychedelic sector gains after report Lilly nears AtaiBeckley acquisition